title: Cytostatic and antitumour properties of a new series of Pt (II) complexes with cyclopentylamine.
abstract: Ten new Pt (II) complexes were synthesized and tested as potential antitumor drugs in vitro on KB human tumour cell line, and in vivo against four experimental tumour systems (P388, L1210, ADJ/PC6A and Yoshida sarcoma). The complexes contained two primary amine ligands (cyclopentylamine) with bidentate leaving ligands consisting of nitro-, dinitro- and sulfo-derivatives of phthalic and isophthalic anions. Various complexes showed a good cytostatic effect in vitro with ID50 from 0.29 and 0.99 mcg/ml. The Pt(cpa)2 (5-sulfo-IPA) appeared to be the most effective compound against P388 and L1210 (T/C% 310 and 250 respectively after three 50 mg/Kg i.p. injections) as well as against ADJ/PC6A (ID90 2.8 mg/kg after a single i.p. injection) and Yoshida sarcoma (T/C% 17.5 after a single 50 mg/kg i.p. injection), but the phthalic acid nitro-derivatives were also quite effective. As far as antileukemic effect was concerned, there was a fairly good correlation between the results in vitro and in vivo. Relationships between antitumour activity and pi electronic charge localization on O- atoms of leaving ligands (M.O. Huckel's Calculations) are also discussed.
authors.affiliation: Department of Inorganic and Analytical Chemistry, Faculty of Pharmacy, University of Madrid, Spain.
authors.forename: D G
authors.initials: DG
authors.lastname: Craciunescu
authors.forename: V
authors.initials: V
authors.lastname: Scarcia
authors.forename: A
authors.initials: A
authors.lastname: Furlani
authors.forename: A
authors.initials: A
authors.lastname: Doadrio
authors.forename: C
authors.initials: C
authors.lastname: Ghirvu
authors.forename: L
authors.initials: L
authors.lastname: Ravalico
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003517:Cyclopentanes; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010984:Platinum / Q000494:pharmacology / Q000627:therapeutic use*; D012513:Sarcoma, Experimental / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D003517:Cyclopentanes; C016329:cyclopentylamine; D010984:Platinum